FrancophonIA/ELRC3.0 huggingface dataset:
English: • In patients whose virus is not resistant to integrase inhibitors, the usual dose is one 50-mg tablet a day; however, when given with certain medicines that decrease the effectiveness of Tivicay the dose is increased to one 50 mg tablet twice a day.
Maltese: • Id-doża hija ta' pillola waħda ta' 50 mg darbtejn kuljum f'pazjenti li virus tagħhom huwa magħruf jew suspettat li hu reżistenti għall-inibituri tal-integrażi; f'dal-pazjenti, l-għoti ta' Tivicay ma'
English: Two studies involved patients who had not previously been treated for HIV:
Maltese: mediċini li jnaqqsu l-effikaċja tiegħu għandu jkun evitat.
English: EU/1/15/1062/001 RAVICTI
Maltese: EU/1/15/1062/001 RAVICTI 1.1 g/ml
English: 1.1 g/ml
Maltese: 25 ml
English: Oral liquid Oral or gastroenteral use bottle (glass) 25 ml
Maltese: Użu orali jew għas-sistema gastroenterali flixkun (ħġieġ)
English: Strength Pharmaceuti cal Form
Maltese: Qawwa Għamla farmaċewtika
English: EU (MA) Number (Invented) name
Maltese: Numru ta' l-EU Isem (ivvintat)
English: 1 bottle + 1 cap adapter
Maltese: Flixkun wieħed + adattatur talgħatu wieħed
English: Pack size
Maltese: Likwidu Orali
English: Cellulose, microcrystalline Pregelatinised maize starch Macrogol 6000
Maltese: Microcrystalline cellulose Pregelatinized maize starch Macrogol 6000
English: Film coating Hypromellose (E464) Titanium dioxide (E171) Red iron oxide (E172) Talc
Maltese: Hypromellose (E464) Titanium dioxide (E171) Red iron oxide (E172) Talc
English: Date of first authorisation: 28/9/2009 Date of latest renewal: 14 May 2014
Maltese: Data tal-ewwel awtorizzazzjoni: 28 ta' Settembru 2009 Data tal-aħħar tiġdid: 14 ta' Mejju 2014
English: България КРКА България ЕООД
Maltese: КРКА България ЕООД Teл.:
English: Proton Pump Inhibitors (PPI):
Maltese: Inibituri tal-Pompa Protonika (Proton Pump Imhibitors, PPI):
English: What Zyllt contains - The active substance is clopidogrel.
Maltese: X'fih Zyllt: - Is-sustanza attiva hi clopidogrel.
English: Równoległa 5, 02-235 Warszawa, Poland KRKA - FARMA d.o.o., V. Holjevca 20/E, 10450 Jastrebarsko, Croatia
Maltese: Równoległa 5, 02-235 Warszawa, Il-Polonja KRKA - FARMA d.o.o., V.
English: Zyllt contains lactose.
Maltese: Zyllt fih lactose.
English: 7 film-coated tablets 14 film-coated tablets 28 film-coated tablets 30 film-coated tablets 50 film-coated tablets 56 film-coated tablets 60 film-coated tablets 84 film-coated tablets 90 film-coated tablets 100 film-coated tablets
Maltese: 7 pilloli miksija b'rita 14-il pillola miksija b'rita 28 pillola miksija b'rita 30 pillola miksija b'rita 50 pillola miksija b'rita 56 pillola miksija b'rita 60 pillola miksija b'rita 84 pillola miksija b'rita 90 pillola miksija b'rita 100 pillola miksija b'rita
English: Blister of OPA/Alu/PVC-Alu containing 7, 14, 28, 30, 50, 56, 60, 84, 90 and 100 film-coated tablets in the box.
Maltese: Folji ta' OPA/AL/PVC-Al li fihom 7, 14, 28, 30, 50, 56, 60, 84, 90 u 100 pillola miksija b'rita fil-kaxxa.
English: Excipients with known effect: Each film-coated tablet contains 108.125 mg lactose.
Maltese: Kull pillola fiha 108.125 mg lactose.
English: Boxes of 7, 14, 28, 30, 50, 56, 60, 84, 90 and 100 film-coated tablets in blisters are available.
Maltese: Kaxxi disponibbli f'7, 14, 28, 30, 50, 56, 60, 84, 90 u 100 pillola miksija b'rita ġo folji.
English: - The other ingredients are lactose (see section 2 ‘Zyllt contains lactose'), microcrystalline cellulose, pregelatinised maize starch, macrogol 6000 and hydrogenated castor oil in the tablet core and hypromellose (E464), titanium dioxide (E171), red iron oxide (E172), talc and propylene glycol in the film-coating.
Maltese: - Is-sustanzi l-oħra fil-qalba tal-pillola huma lactose (ara sezzjoni 2 ‘Zyllt fih lactose'), microcrystalline cellulose, pregelatinized maize starch, macrogol 6000, żejt ir-riġnu idroġenat u hypromellose (E464), titanium dioxide (E171), red iron oxide (E172), talc u propylene glycol fil-kisi tal-pillola.
English: Thrombotic thrombocytopenic purpura (TTP) (see section 4.4), aplastic anaemia, pancytopenia, agranulocytosis, severe thrombocytopenia, acquired haemophilia A, granulocytopenia, anaemia
Maltese: Purpura tromboċitopenikatrombotika (thrombotic thrombocytopenic purpura (TTP)) (ara sezzjoni 4.4), anemija aplastika, panċitopenija, agranuloċitosi, tromboċitopenija severa, emofilja A akwiżita, granuloċitopenija, anemija
English: Other medicines and Zyllt
Maltese: Mediċini oħra u Zyllt
English: The number of patients experiencing the primary endpoint [cardiovascular (CV) death, myocardial infarction (MI), or stroke] was 582 (9.3%) in the clopidogrel-treated group and 719 (11.4%) in the placebo-treated group, a 20% relative risk reduction (95% CI of 10%-28%; p=0.00009) for the clopidogrel-treated group (17% relative risk reduction when patients were treated conservatively, 29% when they underwent percutaneous transluminal coronary angioplasty (PTCA) with or without stent and 10% when they underwent coronary artery bypass graft (CABG)).
Maltese: L-għadd ta' pazjenti li għaddew mill-punt ta' riferiment primarju tat-tmiem [mewt kardjovaskulari (CV), infart mijokardijaku (MI), jew puplesija] kien 582 (9.3 %) fil-grupp trattat b'clopidogrel u 719 (11.4 %) filgrupp trattat bi plaċebo, tnaqqis ta' 20 % fir-risku relattiv (95 % CI ta' 10 %-28 %; p=0.00009) għall-grupp ittrattat b'clopidogrel (tnaqqis fir-riskju relattiv ta' 17 % f'pazjenti li kienu trattati b'mod konservattiv, 29 % meta kellhom angoplastija koronarja transluminali perkutanja (PTCA) bi stent jew mingħajru u 10 % meta kellhom trapjant ta' bajpass f'arterja koronarja (CABG)).
English: Recent myocardial infarction (MI), recent stroke or established peripheral arterial disease The CAPRIE study included 19,185 patients with atherothrombosis as manifested by recent myocardial infarction (<35 days), recent ischaemic stroke (between 7 days and 6 months) or established peripheral arterial disease (PAD).
Maltese: Infart mijokardjali riċenti (MI), puplesija riċenti jew mard periferali stabbilit tal-arterji L-istudju CAPRIE kien jinkludi 19,185 pazjent b'aterotrombosi li ntweriet permezz ta' infart mijokardjali riċenti (<35 jum), puplesija iskemika riċenti (bejn 7 ijiem u 6 xhur) jew mard stabbilit tal-arterji periferali (peripheral arterial disease (PAD)).
English: In vitro and in vivo, clopidogrel is metabolised according to two main metabolic pathways: one mediated by esterases and leading to hydrolysis into its inactive carboxylic acid derivative (85% of circulating metabolites), and one mediated by multiple cytochromes P450.
Maltese: In vitro u in vivo, clopidogrel jiġi mmetabolizzat permezz ta' żewġ sensiliet ta' reazzjonijiet metaboliċi: waħda bl-intervent ta' esterases u li twassal għallidroliżi fid-derivattiv inattiv tiegħu carboxylic acid (85% tal-metaboliti fiċ-ċirkulazzjoni), u waħda blintervent ta' ċitokromi P450 multipli. Clopidogrel jiġi mmetabolizzat l-ewwel f'metabolit intermedjarju 2
English: In a subgroup analysis by qualifying condition (myocardial infarction, ischaemic stroke, and PAD) the benefit appeared to be strongest (achieving statistical significance at p = 0.003) in patients enrolled due to PAD (especially those who also had a history of myocardial infarction) (RRR = 23.7%; CI: 8.9 to 36.2) and weaker (not significantly different from ASA) in stroke patients (RRR = 7.3%; CI: -5.7 to 18.7 [p=0.258]).
Maltese: F'analiżi tas-sottogrupp permezz ta' kundizzjoni kwalifikanti (infart mijokardijaku, puplesija iskemika, u PAD) il-benefiċċju jidher li kien l-akbar (fejn intlaħqet rilevanza statistika b'p = 0.003) f'pazjenti li ddaħħlu minħabba PAD (speċjalment dawk li kellhom ukoll storja medika ta' infart mijokardijaku) (RRR = 23.7 %; CI: 8.9 sa 36.2) u aktar dgħajjef (mhux differenti b'mod sinifikanti minn ASA) f'pazjenti b'puplesija (RRR = 7.3 %; CI: -5.7 sa 18.7 [p=0.258]).
English: There was no statistically significant difference in the rates of fatal bleeding (1.1% in the clopidogrel + ASA group and 0.7% in the placebo +ASA group) and haemorrhagic stroke (0.8% and 0.6%, respectively) between groups.
Maltese: Ma kien hemm ebda differenza statistikamentsinifikanti bejn iż-żewġ gruppi fir-rata ta' fsada li twassal għall-mewt (1.1% fil-grupp clopidogrel + ASA u 0.7% fil-grupp plaċebo +ASA) u fir-rata ta' puplesija emorraġika (0.8% u 0.6%, rispettivament).
English: - efavirenz, a medicine to treat HIV (human immunodeficiency virus) infections, - carbamazepine a medicine to treat some forms of epilepsy, - moclobemide, medicine to treat depression, - repaglinide, medicine to treat diabetes, - paclitaxel, medicine to treat cancer, - anti-retroviral medicines (medicines to treat HIV infections).
Maltese: - repaglinide, mediċina għat-trattament tad-dijabete, - paclitaxel, mediċina għat-trattament tal-kanċer, - mediċini antiretrovirali (mediċini għall-kura ta' infezzjonijiet bl-HIV).
English: There was an excess of intracranial bleeding in the clopidogrel + ASA treatment group compared to the placebo + ASA group (1.4% versus 0.8%, respectively).
Maltese: Kien hemm iżjed fsada ġewwa l-kranju fil-grupp ta' kura clopidogrel + ASA meta mqabbel mal grupp plaċebo + ASA (1.4% kontra 0.8%, rispettivament).
English: Zyllt contains lactose
Maltese: Zyllt fih lactose
English: Zyllt 75 mg film-coated tablets clopidogrel
Maltese: Zyllt 75 mg pilloli miksija b'rita Clopidogrel
English: Patients were randomised to clopidogrel (300 mg loading dose followed by 75 mg/day, N=6,259) or placebo (N=6,303), both given in combination with ASA (75-325 mg once daily) and other standard therapies.
Maltese: Il-pazjenti kienu każwalment magħżula għal clopidogrel (b'doża tal-bidu ta' 300 mg segwita b'75 mg/jum, N=6,259) jew plaċebo (N=6,303), li t tnejn ingħataw flimkien ma' ASA (75-325 mg darba kuljum) u terapiji standard oħra.
English: However, patients entered into clinical trials with clopidogrel received a variety of concomitant medicinal products including diuretics, beta blockers, ACEI, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents, and GPIIb/IIIa antagonists without evidence of clinically significant adverse interactions.
Maltese: Madankollu, pazjenti li daħlu fi studji kliniċi bi clopidogrel ngħataw varjeta` ta' prodotti mediċinali fl-istess ħin u dawn kienu jinkludu dijuretiċi, beta blockers ACEI, antagonisti tal-kalċju, sustanzi li jbaxxu l-kolesterol, vasodilataturi koronarji, sustanzi kontra d-dijabete (inkluża linsulina), sustanzi antiepilettiċi u antagonisti GPIIb/IIIa mingħajr ma kien hemm evidenza ta' interazzjonijiet avversi klinikament sinifikanti.
English: Their frequency is defined using the following conventions: common (1/100 to <1/10); uncommon (1/1,000 to <1/100); rare (1/10,000 to <1/1,000); very rare (<1/10,000), not known (cannot be estimated from the available data).
Maltese: Il-frekwenza tagħhom hi definita skont dawn il-konvenzjonijiet: komuni (≥1/100 sa <1/10); mhux komuni (≥1/1,000 sa <1/100); rari (≥1/10,000 sa <1/1,000); rari ħafna (<1/10,000), mhux magħruf (ma tistax tittieħed stima mid-data disponibbli).F'kull sistema tal-klassifika ta' l-organi, l-effetti mhux mixtieqa huma mniżżla skond is-serjeta' tagħhom, bl-aktar serji jitniżżlu l-ewwel.
English: Reproductive systems and breast disorders
Maltese: Disturbi fissistema riproduttiva u fis-sider
English: Each film-coated tablet contains 75 mg of clopidogrel (as hydrogen sulphate).
Maltese: Kull pillola miksija b'rita fiha 75 mg clopidogrel (bħala hydrogen sulphate).
English: Zyllt 75 mg film-coated tablets
Maltese: Zyllt 75 mg pilloli miksija b'rita
English: Thrombolytics: the safety of the concomitant administration of clopidogrel, fibrin or non-fibrin specific thrombolytic agents and heparins was assessed in patients with acute myocardial infarction.
Maltese: Trombolitiċi: is-sigurtà tat-teħid flimkien ta' clopidogrel, sustanzi trombolitiċi speċifiċi tal-fibrini u mhux fibrini u heparins ġiet eżaminata f'pazjenti li kellhom infart mijokardijaku akut.
English: If you have experienced severe chest pain (unstable angina or heart attack), your doctor may give you 300 mg of Zyllt (4 tablets of 75 mg) once at the start of treatment.
Maltese: Jekk kellek uġigħ sever f'sidrek (anġina instabbli jew attakk tal-qalb), it-tabib jista' jagħtik 300 mg ta' Zyllt (4 pilloli ta' 75 mg) fil-bidu tal-kura.
English: You should specifically tell your doctor if you take - medicines that may increase your risk of bleeding such as: o oral anticoagulants, medicines used to reduce blood clotting, o a non-steroidal anti-inflammatory medicine, usually used to treat painful and/or inflammatory conditions of muscle or joints, o heparin or any other injectable medicine used to reduce blood clotting, o ticlopidine, other antiplatelet agent, o a selective serotonin reuptake inhibitor (including but not restricted to fluoxetine or fluvoxamine), medicines usually used to treat depression, - omeprazole or esomeprazole, medicines to treat upset stomach, - fluconazole or voriconazole, medicines to treat fungal infections,
Maltese: Għandek speċifikament tgħid lit-tabib tiegħek jekk tieħu - mediċini li jistgħu jżidu r-riskju li inti jkollok xi fsada bħal: - sustanzi kontra l-koagulazzjoni tad-demm li jittieħdu mill-ħalq, mediċini li jraqqu d-demm, - mediċina li hija anti-infjammatorju li mhux sterojde, normalment użat biex jiġi ittrattat l-uġigħ u/jew kundizzjonijiet infjammatorji tal- muskoli jew tal-ġogi, - heparin jew xi mediċina oħra li tinjetta biex traqqaq id-demm, - ticlopidine, sustanzi oħra kontra l-plejtlets, - inibitur selettiv tal-ġbir mill-ġdid ta' serotonin (li jinkludi iżda mhux limitat għal fluoxetine jew fluvoxamine), mediċini li ssoltu jintużaw fil-kura tad-dipressjoni, - omeprazole jew esomeprazole, mediċini għat-taqlib tal-istonku, - fluconazole jew voriconazole, mediċini li jittrattaw infezzjonijiet tal-fungu, - carbamazepine, mediċini li jittrattaw xi tip ta' epilessija,
English: The elimination halflife of the main circulating (inactive) metabolite was 8 hours after single and repeated administration.
Maltese: Il-half-life tat-tneħħija tal-metabolit prinċipali (inattiv) ċirkolanti kien 8 sigħat wara amministrazzjoni waħda u ripetuta.
English: film-coated tablet
Maltese: Disturbi filqalb
English: Patients received clopidogrel (75 mg/day, n=22,961) or placebo (n=22,891), in combination with ASA (162 mg/day), for 28 days or until hospital discharge.
Maltese: Il-pazjenti ngħataw clopidogrel (75 mg/jum, n=22,961) jew il-plaċebo
English: Detailed information on this medicine is available on the European Medicines Agency web site: http://www.ema.europa.eu/.
Maltese: Informazzjoni dettaljata dwar din il-mediċina tinsab fuq is-sit elettroniku tal-Aġenzija Ewropea għallMediċini http://www.ema.europa.eu.
English: Breast-feeding
Maltese: Clopidogrel
English: The active metabolite of clopidogrel selectively inhibits the binding of adenosine diphosphate (ADP) to its platelet P2Y12 receptor and the subsequent ADP-mediated activation of the glycoprotein GPIIb/IIIa complex, thereby inhibiting platelet aggregation.
Maltese: Il-metabolit attiv ta' clopidogrel jimpedixxi b'mod selettiv l-irbit ta' adenosine diphosphate (ADP) mar-riċettur tal-plejtlits P2Y12 u l-attivazzjoni suċċessiva tal-kumpless ta' glikoproteina
English: Musculoskeletal, connective tissue and bone disorders
Maltese: Disturbi muskoluskeletrali, tattessut konnettiv u fl-għadam
English: You have been prescribed Zyllt to help prevent blood clots and reduce the risk of these severe events because: - You have a condition of hardening of arteries (also known as atherosclerosis), and - You have previously experienced a heart attack, stroke or have a condition known as peripheral arterial disease, or - You have experienced a severe type of chest pain known as ‘unstable angina' or ‘myocardial infarction' (heart attack).
Maltese: - Għandek kundizzjoni fejn qed jibbiesu l-arterji (magħrufa wkoll bħala atherosklerosi), u - Inti kellek attakk f'qalbek, puplesija jew għandek kundizzjoni magħrufa bħala mard arterjali periferiku jew - kellek uġigħ sever fis-sider magħruf bħala ‘anġina instabbli' jew ‘infart mijokardjali' (attakk tal-qalb).
English: Manufacturer
Maltese: Gajnikomastja
English: The full EPAR for Sustiva can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Maltese: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: This summary was last updated in 12-2017.
Maltese: Dan is-sommarju ġie aġġornat l-aħħar f'12-2017.
English: The active substance in Sustiva, efavirenz, is a non-nucleoside reverse transcriptase inhibitor (NNRTI).
Maltese: Is-sustanza attiva f'Sustiva, efavirenz, hija inibitur mhux nukleosidiku tat-traskriptażi inversa (NNRTI, non-nucleoside reverse transcriptase inhibitor).
English: Other information about Sustiva
Maltese: Informazzjoni oħra dwar Sustiva
English: The recommended dose of Sustiva for adults is 600 mg once a day.
Maltese: Id-doża rakkomandata ta' Sustiva għall-adulti hija 600 mg darba kuljum.
English: Similar results have been seen in studies involving 182 patients (of whom 177 were children aged between 3 months and 18 years) in combination with nelfinavir and other antiviral medicines.
Maltese: Dehru riżultati simili fi studji li involvew 182 pazjent (li minnhom 177 kienu tfal ta' etajiet bejn 3 xhur u 18-il sena) flimkien ma' nelfinavir u mediċini antivirali oħra.
English: This is a summary of the European public assessment report (EPAR) for Sustiva.
Maltese: Dan id-dokument huwa sommarju tar-rapport pubbliku Ewropew ta' valutazzjoni (EPAR) għal Sustiva.
English: Why is Sustiva approved?
Maltese: Għaliex ġie approvat Sustiva?
English: Sustiva is an antiviral medicine that is used together with other antiviral medicines to treat patients aged 3 months or older and weighing at least 3.5 kg, who are infected with human immunodeficiency virus type 1 (HIV-1), a virus that causes acquired immune deficiency syndrome (AIDS).
Maltese: Sustiva huwa mediċina antivirali li jintuża flimkien ma' mediċini antivirali oħra biex jikkura pazjenti ta' 3 xhur jew akbar u li jiżnu tal-inqas 3.5 kg, li huma infettati bil-virus tal-immunodefiċjenza umana tattip 1 (HIV-1), virus li jikkawża s-sindrome tal-immunodefiċjenza akkwiżita (AIDS).
English: The Sustiva combination was more effective than the combination without Sustiva: 70% and 30% of the patients, respectively, had viral loads below 500 copies/ml after 48 weeks;
Maltese: Il-kombinazzjoni ta' Sustiva kienet aktar effettiva millkombinazzjoni mingħajr Sustiva: 70 % u 30% tal-pazjenti, rispettivament, kellhom tagħbiji virali taħt il-500 kopja/ml wara 48 ġimgħa;
English: 67% of the adults treated with Sustiva in combination with zidovudine and lamivudine had viral loads below 400 copies/ml after 48 weeks, compared with 54% of the patients treated with Sustiva and indinavir, and 45% of the patients treated with indinavir, lamivudine and zidovudine;
Maltese: • fl-ewwel studju, Sustiva flimkien ma' lamivudine u zidovudine jew ma' indinavir (mediċini antivirali oħra), tqabbel mal-kombinazzjoni ta' indinavir, lamivudine u zidovudine. 67 % tal-adulti kkurati b'Sustiva flimkien ma' zidovudine u lamivudine kellhom tagħbiji virali taħt l-400 kopja/ml wara 48 ġimgħa, meta mqabbla ma' 54 % tal-pazjenti kkurati b'Sustiva u indinavir, u 45 % tal-pazjenti kkurati b'indinavir, lamivudine u zidovudine;
English: Sustiva has shown benefit in controlling HIV infection in three main studies involving over 1,100 adults.
Maltese: Sustiva wera benefiċċju fil-kontroll tal-infezzjoni tal-HIV fi tliet studji ewlenin li involvew ‘il fuq minn 1,100 adult.
English: It blocks the activity of reverse transcriptase, an enzyme produced by HIV that allows it to reproduce itself in the cells it has infected.
Maltese: Din timblokka l-attività tat-traskriptażi inversa, enzima prodotta mill-HIV li jippermettilha tirriproduċi lilha nnifisha fiċ-ċelloli li tkun infettat.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Sustiva on 28 May 1999.
Maltese: Il-Kummissjoni Ewropea tat awtorizzazzjoni għat-tqegħid fis-suq valida fl-Unjoni Ewropea kollha għal Sustiva fit-28 ta' Mejju 1999.
English: It is available as capsules and tablets and must be given in combination with other antiviral medicines.
Maltese: Dan jiġi bħala kapsuli u pilloli u għandu jingħata flimkien ma' mediċini antivirali oħra.
English: The European Medicines Agency decided that Sustiva's benefits are greater than its risks in antiviral combination treatment of HIV-infected adults, adolescents and children three months of age and older and recommended that it be approved for use in the EU.
Maltese: L-Aġenzija Ewropea għall-Mediċini ddeċidiet li l-benefiċċji ta' Sustiva huma akbar mir-riskji tiegħu filkura kombinata antivirali ta' adulti, adolexxenti u tfal ta' età ta' tliet xhur jew aktar infettati bl-HIV u rrakkomandat li jkun approvat għall-użu fl-UE.
English: Taking Sustiva with food may lead to an increase in the frequency of side effects.
Maltese: It-teħid ta' Sustiva mal-ikel jista' jwassal għal żieda fil-frekwenza ta' effetti sekondarji.
English: The Agency noted that Sustiva has not been studied adequately in patients with advanced disease (CD4 cell counts below 50 cells/mm3) or after treatment with protease inhibitors (another type of antiviral medicine) that was not working.
Maltese: L-Aġenzija nnutat li Sustiva ma ġiex studjat biżżejjed f'pazjenti b'marda avvanzata (għadd ta' ċelloli CD4 inqas minn 50 ċellola/mm3) jew wara kura b'inibituri tal-proteażi (tip ieħor ta' mediċina antivirali) li ma kinitx qed taħdem.
English: In all of the studies, the main measure of effectiveness was the number of patients with undetectable levels of HIV 1 in their blood (viral loads) after 24 or 48 weeks of treatment:
Maltese: Fl-istudji kollha, il-kejl ewlieni tal-effettività kien in-numru ta' pazjenti b'livelli ta' HIV 1 li ma jistgħux jiġu osservati fid-demm tagħhom (tagħbiji virali) wara kura ta' 24 jew 48 ġimgħa:
English: • the third study compared adding Sustiva or placebo (a dummy treatment) to a combination of antiviral medicines that included indinavir and two other antiviral medicines, in patients who had already been receiving treatment for HIV infection.
Maltese: • it-tielet studju qabbel iż-żieda ta' Sustiva jew plaċebo (kura finta) ma' kombinazzjoni ta' mediċini antivirali li kienu jinkludu indinavir u żewġ mediċini antivirali oħra, f'pazjenti li diġà kienu qed jirċievu kura għall-infezzjoni tal-HIV.
English: Sustiva can affect the electrical activity of the heart and so must also not be used in patients with heart problems such as changes in heart rhythm and activity, slow heart rate or heart failure or other conditions that can affect the heart's electrical activity, or who have close relatives that have died suddenly from a heart condition or were born with heart problems.
Maltese: Sustiva jista' jaffettwa l-attività elettrika tal-qalb u għalhekk m'għandux jintuża wkoll f'pazjenti bi problemi tal-qalb bħal tibdil fir-ritmu jew fl-attività tal-qalb, rata tal-qalb bil-mod jew insuffiċjenza kardijaka jew kondizzjonijiet oħra li jistgħu jaffettwaw l-attività elettrika tal-qalb, jew li għandhom qraba viċini li mietu f'daqqa minn kondizzjoni tal-qalb jew li twieldu bi problemi tal-qalb.
English: What are the risks associated with Sustiva?
Maltese: X'inhuma r-riskji assoċjati ma' Sustiva?
English: • the second study compared Sustiva in combination with nelfinavir and two other antiviral medicines with the same combination without Sustiva.
Maltese: • it-tieni studju qabbel Sustiva flimkien ma' nelfinavir u żewġ mediċini antivirali oħra mal-istess kombinazzjoni mingħajr Sustiva.
English: Sustiva is also commonly associated with dizziness, headache, nausea (feeling sick) and tiredness.
Maltese: Sustiva huwa assoċjat ukoll b'mod komuni ma' sturdament, uġigħ ta' ras, nawsja (tħossok ma tiflaħx) u għeja.
English: It is recommended that Sustiva be taken on an empty stomach and without food, preferably at bedtime.
Maltese: Huwa rakkomandat li Sustiva jittieħed fuq stonku vojt u mingħajr ikel, preferibbilment qabel il-ħin tal-irqad.